An easy-to-handle DPD deficiency test in saliva to identify patients at high-risk for life-threatening toxicity due to fluoropyrimidine therapy

Date 28 June 2017
Event ESMO World Congress on Gastrointestinal Cancer 2017
Session ESMO World Congress on Gastrointestinal Cancer 2017
Topics Gastrointestinal Cancers
Palliative and Supportive Care
Presenter Gilberto Schwartsmann
Citation Annals of Oncology (2017) 28 (suppl_3): iii13-iii136. 10.1093/annonc/mdx261
Authors G. Schwartsmann, M. Venzon Antunes
  • /


Background: Severe dihydropyrimidine dehydrogenase (DPD) deficiency can be lethal in 0.5-3.0% of patients receiving fluoropyrimidines. Unfortunately, there is no routine test in medical practice to identify high-risk patients. Here, we evaluated the use of plasma and saliva uracil (U) to dihydrouracil (UH2) metabolic ratio and DPYD genotyping, as a means to identify patients with DPD deficiency and fluoropyrimidine toxicity. In addition, we report on a functional test using UH2/U metabolic ratio in dried saliva spots (DSS)